# ARCAGY-GINECO

Source: https://onco.cc/companies/arcagy-gineco/  
OnCo record `arcagy-gineco` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.

## Summary

GINECO was founded in 1993 as France's cooperative group for ovarian, endometrial, cervical and rare gynaecologic cancers, with ARCAGY as its academic sponsor and research organisation. As a founding member of the European ENGOT network and the Gynecologic Cancer InterGroup, it led PAOLA-1/ENGOT-ov25, which showed olaparib plus bevacizumab maintenance improves progression-free and, in HRD-positive disease, overall survival in newly diagnosed ovarian cancer. GINECO also ran the CHIVA and ICON7 contributions, elderly-specific ovarian trials and the rare-tumour TMRG network, and it co-develops immunotherapy trials in endometrial and cervical cancer with the GOG Foundation.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: GINECO; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens; ARCAGY
- Tags: cooperative-group
- HQ: Paris
- Type: cooperative-group
- Website: https://www.arcagy.org

## Notes

- PAOLA-1 (olaparib plus bevacizumab)
- Elderly ovarian cancer trials
- ENGOT and GCIG leadership
- Rare gynaecologic tumours network

## Sources

- ARCAGY-GINECO: https://www.arcagy.org

## Connected records

- drugs: [Niraparib](https://onco.cc/drugs/niraparib/), [Olaparib](https://onco.cc/drugs/olaparib/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [HRD & BRCA testing](https://onco.cc/technologies/hrd-testing/), [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- companies: [EORTC](https://onco.cc/companies/curie-nki-eortc/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [UNICANCER](https://onco.cc/companies/unicancer/)
- terms: [Homologous recombination deficiency (HRD)](https://onco.cc/terms/hrd/)
- trials: [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/), [PAOLA-1 / ENGOT-ov25](https://onco.cc/trials/paola-1/)
- people: [Isabelle Ray-Coquard](https://onco.cc/people/isabelle-ray-coquard/), [Sébastien Armanet](https://onco.cc/people/sebastien-armanet/)
- institutions: [European Society of Gynaecological Oncology](https://onco.cc/institutions/esgo/)

---
JSON: https://onco.cc/api/v1/entities/arcagy-gineco.json